What is Craif?
Craif is at the forefront of developing groundbreaking methods for disease detection and treatment optimization, with a particular focus on utilizing urine-based exosome collection technology. The company's pioneering approach aims to establish accurate, painless, and early disease detection systems, contributing to a future where proactive health management is universally accessible. This aligns with their mission to enable individuals to maintain lifelong health.
How much funding has Craif raised?
Craif has raised a total of $28.3M across 2 funding rounds:
Series C
$6.3M
Series C
$22M
Series C (2024): $6.3M, investors not publicly disclosed
Series C (2025): $22M led by Aozora Bank and Unreasonable Group
Key Investors in Craif
Aozora Bank
Aozora Bank, a Japanese financial institution established in 1957, provides a comprehensive suite of banking services, including foreign currency deposits and various account types. Their involvement suggests a strategic financial partnership to support Craif's growth.
Unreasonable Group
Unreasonable Group is dedicated to supporting entrepreneurs who tackle critical global challenges through its accelerator programs and investment funds. Their participation indicates a belief in Craif's potential to solve significant healthcare problems.
What's next for Craif?
The recent major enterprise-level funding positions Craif for significant scaling and further research and development. This strategic backing will likely accelerate the refinement of their exosome collection technology and the expansion of their diagnostic capabilities. The company is poised to solidify its position as a leader in non-invasive diagnostics, potentially transforming early disease detection across a wide spectrum of conditions.
See full Craif company page
